Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Quercetin in Secondary Progressive Multiple Sclerosis
NCT07270120Phase 1Not yet recruiting
- Sponsor
- The Ohio State University
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib and quercetin in secondary-progressive multiple sclerosis (SPMS), sponsored by The Ohio State University. Primary endpoints: Participant retention rate at 3 months, Recruitment feasibility at 0 months and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT07270120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270120.